These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31593523)

  • 1. A Content Analysis of Patient Advocacy Organization Policies Addressing Institutional Conflicts of Interest.
    Brems JH; McCoy MS
    AJOB Empir Bioeth; 2019; 10(4):215-221. PubMed ID: 31593523
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
    Rose SL; Highland J; Karafa MT; Joffe S
    JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.
    Li DG; Singer S; Mostaghimi A
    JAMA Dermatol; 2019 Apr; 155(4):460-464. PubMed ID: 30698625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Potential Conflicts of Interest among Otolaryngologic Patient Advocacy Organizations in 2016.
    Kondamuri NS; Rathi VK; Naunheim MR; Sethi RV; Miller AL; Varvares MA
    Otolaryngol Head Neck Surg; 2019 Dec; 161(6):967-969. PubMed ID: 31479391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.
    Rose SL
    J Law Med Ethics; 2013; 41(3):680-7. PubMed ID: 24088159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest.
    Ehrlich O; Wingate L; Heller C; de Melo-Martin I
    BMC Med Ethics; 2019 Dec; 20(1):96. PubMed ID: 31847854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.
    Ball DE; Tisocki K; Herxheimer A
    BMC Public Health; 2006 Aug; 6():201. PubMed ID: 16887025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Policies on faculty conflicts of interest at US universities.
    Cho MK; Shohara R; Schissel A; Rennie D
    JAMA; 2000 Nov; 284(17):2203-8. PubMed ID: 11056591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A national survey of policies on disclosure of conflicts of interest in biomedical research.
    McCrary SV; Anderson CB; Jakovljevic J; Khan T; McCullough LB; Wray NP; Brody BA
    N Engl J Med; 2000 Nov; 343(22):1621-6. PubMed ID: 11096171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
    Kang SY; Bai G; Karas L; Anderson GF
    Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.
    Rothman SM; Raveis VH; Friedman A; Rothman DJ
    Am J Public Health; 2011 Apr; 101(4):602-9. PubMed ID: 21233424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants.
    Weinfurt KP; Dinan MA; Allsbrook JS; Friedman JY; Hall MA; Schulman KA; Sugarman J
    Acad Med; 2006 Feb; 81(2):113-8. PubMed ID: 16436571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond Disclosure: Developing Law and Policy to Tackle Corporate Influence.
    Marks JH
    Am J Law Med; 2020 May; 46(2-3):275-296. PubMed ID: 32659196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression.
    Cosgrove L; Krimsky S; Wheeler EE; Peters SM; Brodt M; Shaughnessy AF
    Account Res; 2017; 24(2):99-115. PubMed ID: 27901595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conflicts of interest in psychiatry: strategies to cultivate literacy in daily practice.
    Shimazawa R; Ikeda M
    Psychiatry Clin Neurosci; 2014 Jul; 68(7):489-97. PubMed ID: 24802771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A turning point for conflicts of interest: the controversy over the National Academy of Sciences' first conflicts of interest disclosure policy.
    Parascandola M
    J Clin Oncol; 2007 Aug; 25(24):3774-9. PubMed ID: 17704427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase.
    Shnier A; Lexchin J; Romero M; Brown K
    BMC Health Serv Res; 2016 Aug; 16(a):383. PubMed ID: 27528247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding disclosure: Comparing conflict of interest policy among the United States, France, and Australia.
    Grundy Q; Habibi R; Shnier A; Mayes C; Lipworth W
    Health Policy; 2018 May; 122(5):509-518. PubMed ID: 29605526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disclosure, transparency, and accountability: a qualitative survey of public sector pharmaceutical committee conflict of interest policies in the World Health Organization South-East Asia Region.
    Grundy Q; Parker L; Wong A; Fusire T; Dimancesco D; Tisocki K; Walkowiak H; Vian T; Kohler J
    Global Health; 2022 Mar; 18(1):33. PubMed ID: 35303902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financial Relationships between Organizations That Produce Clinical Practice Guidelines and the Biomedical Industry: A Cross-Sectional Study.
    Campsall P; Colizza K; Straus S; Stelfox HT
    PLoS Med; 2016 May; 13(5):e1002029. PubMed ID: 27244653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.